Evaluating a new imaging agent for cancer detection
Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73
EARLY_PHASE1 · First Affiliated Hospital of Fujian Medical University · NCT06995976
This study is testing a new imaging agent for cancer to see if it works better than the standard method in helping doctors find tumors.
Quick facts
| Phase | EARLY_PHASE1 |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | First Affiliated Hospital of Fujian Medical University (other) |
| Drugs / interventions | radiation, immunotherapy |
| Locations | 1 site (Fuzhou, Fujian) |
| Trial ID | NCT06995976 on ClinicalTrials.gov |
What this trial studies
This study investigates the safety and effectiveness of a novel PET radiotracer, 68Ga-dPNE, which targets CD73, an enzyme linked to tumor immune evasion. The research involves assessing the biodistribution and radiation dosimetry of 68Ga-dPNE in human volunteers and comparing its diagnostic efficacy with the standard imaging agent 18F-FDG. By focusing on various cancers, the study aims to enhance imaging techniques that could improve cancer diagnosis and treatment monitoring.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with cancers that express CD73, such as breast, liver, gastric, colorectal, and ovarian cancers.
Not a fit: Patients who are pregnant, lactating, or have severe hepatic and renal insufficiency may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved imaging techniques for better diagnosis and treatment of various cancers.
How similar studies have performed: Other studies have shown promise with similar imaging approaches, but the specific application of 68Ga-dPNE is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Signed informed consent and be able to follow up. Exclusion Criteria: Pregnant or lactational women; who suffered from severe hepatic and renal insufficiency.
Where this trial is running
Fuzhou, Fujian
- The First Affiliated Hospital of Fujian Medical University — Fuzhou, Fujian, China (RECRUITING)
Study contacts
- Principal investigator: Weibing Miao, MD — First Affiliated Hospital of Fujian Medical University
- Study coordinator: Weibing Miao, MD
- Email: miaoweibing@126.com
- Phone: +86-0591-87981618
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Malignant Tumour